Search the Newsreel

Walleye Capital LLC Buys Shares of 106,112 ANI Pharmaceuticals, Inc. $ANIP

Walleye Capital LLC has acquired a new position in ANI Pharmaceuticals, purchasing 106,112 shares valued at approximately $8.8 million, indicating growing institutional interest as hedge funds and other investors collectively own 76.05% of the company. ANI Pharmaceuticals recently surpassed quarterly earnings expectations, reporting adjusted …

Stack Financial Management Inc Makes New $41.30 Million Investment in L3Harris Technologies Inc $LHX

Stack Financial Management Inc has made a new investment of $41.30 million in L3Harris Technologies Inc (NYSE:LHX), acquiring 142,143 shares during the second quarter. This investment represents approximately 3.2% of Stack Financial Management Inc's portfolio, making L3Harris Technologies its seventh-largest holding. Other hedge funds …

Spyglass Pharma (NASDAQ:SGP) Upgraded to "Moderate Buy" at Raymond James Financial

Trifecta Capital Advisors LLC Purchases New Position in Vertex Pharmaceuticals Incorporated $VRTX

Trifecta Capital Advisors LLC has acquired a new position in Vertex Pharmaceuticals (NASDAQ:VRTX), purchasing 16,745 shares valued at approximately $8.318 million, making it their 27th largest holding. Other institutional investors like Capital Research Global Investors and State Street Corp also increased their stakes. This …

16,416 Shares in L3Harris Technologies Inc $LHX Acquired by Trifecta Capital Advisors LLC

Trifecta Capital Advisors LLC has acquired a new stake of 16,416 shares in L3Harris Technologies Inc (NYSE:LHX) during the second quarter, valued at approximately $4.77 million. This move is part of broader institutional investor activity, with several other firms also adjusting their positions in …

Oppenheimer Asset Management Inc. Makes New Investment in Vertex Pharmaceuticals Incorporated $VRTX

Oppenheimer Asset Management Inc. has acquired a new stake of 17,931 shares in Vertex Pharmaceuticals (NASDAQ:VRTX), valued at approximately $8.91 million during the second quarter. This new investment comes as other institutional investors have also adjusted their holdings in VRTX. Vertex Pharmaceuticals reported earnings …

Mill Capital Management LLC Invests $18.06 Million in L3Harris Technologies Inc $LHX

Mill Capital Management LLC has acquired a new position in L3Harris Technologies Inc (NYSE:LHX), purchasing 62,134 shares valued at approximately $18.06 million, making it their 24th largest holding. Other institutional investors have also adjusted their stakes in LHX. The company recently reported strong quarterly …

Jennison Associates LLC Has $28.60 Million Stock Holdings in Nicolet Bankshares Inc. $NIC

Walleye Capital LLC Acquires Shares of 179,992 Southern First Bancshares, Inc. $SFST

Walleye Capital LLC has acquired 179,992 shares of Southern First Bancshares, Inc. (NASDAQ:SFST) in the second quarter, valued at approximately $11.0 million, representing about 1.9% of the company. Institutional investors now collectively own 75% of SFST. Analysts maintain a positive outlook with a consensus …

86,249 Shares in Eton Pharmaceuticals, Inc. $ETON Acquired by Walleye Capital LLC

Walleye Capital LLC has acquired 86,249 shares of Eton Pharmaceuticals, Inc. (NASDAQ:ETON) during the second quarter, valued at approximately $3.12 million, representing a 0.31% stake in the company. This acquisition comes as Eton Pharmaceuticals reported strong quarterly results, exceeding revenue and EPS expectations, and …

Quantinno Capital Management LP Buys 24,878 Shares of Crinetics Pharmaceuticals, Inc. $CRNX

Quantinno Capital Management LP significantly increased its stake in Crinetics Pharmaceuticals, Inc. (CRNX) by 280.9% in Q1, acquiring an additional 24,878 shares to reach a total of 33,734 shares valued at $1.225 million. This comes as Crinetics Pharmaceuticals reported strong Q1 revenues of $25.12 …

California State Teachers Retirement System Grows Stock Holdings in Urogen Pharma $URGN

The California State Teachers Retirement System significantly increased its holdings in Urogen Pharma (NASDAQ:URGN) by 1,605.5% in the first quarter, now owning 38,750 shares valued at $697,000. Institutional investors collectively hold 91.29% of the company, which has an average analyst rating of "Moderate Buy" …

How Investors May Respond To ANI Pharmaceuticals (ANIP) Record Q2 Results And Reaffirmed 2026 Revenue Guidance

Crinetics Pharmaceuticals (CRNX) Reports Q2 2026 Results, Is The Stock About Right?

ARS Pharmaceuticals (SPRY) Stock Faces Margin Squeeze As Losses Deepen

Assenagon Asset Management S.A. Has $1.18 Million Stock Position in First Citizens BancShares, Inc. $FCNCA

Understanding the Setup: (ABVX) and Scalable Risk

This article provides an analysis of Abivax Sa (NASDAQ: ABVX), highlighting a weak near-term sentiment but potential long-term strength. It details specific AI-generated trading strategies including long, breakout, and short positions, along with support and resistance levels across different time horizons. The analysis suggests …

Walleye Capital LLC Invests $4.84 Million in Xeris Biopharma Holdings, Inc. $XERS

Walleye Capital LLC has invested $4.84 million in Xeris Biopharma Holdings, Inc. by acquiring 611,296 shares in the second quarter, representing 0.35% of the company. Institutional investors collectively own 42.75% of Xeris. Despite reporting higher-than-expected revenue of $92.1 million, the company posted an adjusted …

Walleye Capital LLC Buys New Position in Xenon Pharmaceuticals Inc. $XENE

Walleye Capital LLC has acquired a new position in Xenon Pharmaceuticals Inc. (NASDAQ:XENE), purchasing 76,955 shares valued at approximately $4.65 million. This move is amidst positive analyst sentiment with a "Buy" rating and a $77.13 average price target, despite recent insider stock sales totaling …

Wetour Robotics Stock Jumps 128%, but $0.90 Share Sale Could Dilute Holders 65%

Wetour Robotics (NASDAQ:WETO) shares surged 128% on Friday, closing at $8.22, following the announcement of a deeply discounted private share sale. The company plans to sell 2 million ordinary shares at $0.90 each, which could lead to significant dilution for existing shareholders, representing approximately …

Indivior Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:INDV

Helix Acquisition Corp III Posts Q2 Profit on IPO Trust Interest

Helix Acquisition Corp. III (Nasdaq: HLXC) reported a net income of $1.33 million for the second quarter of 2026, stemming from interest earned on its IPO trust account. The company, a SPAC, completed a $172.5 million IPO in January 2026 and now holds $175.05 …

Amylyx Pharmaceuticals (AMLX) Stock Trades At A Premium After Avexitide Trial Progress

Amylyx Pharmaceuticals (AMLX) stock has seen a 170.4% return over the past year, but its valuation metrics suggest it is trading at a premium. The progress of the avexitide trial, including its completed pivotal trial and potential commercial launch, supports future cash flow expectations, …

Redcare Pharmacy Aktie • A2AR94 • NL0012044747

Madrigal’s Rezdiffra Hits $1.3B Run Rate as MASH Pipeline Expands

Madrigal Pharmaceuticals' drug Rezdiffra achieved a $1.3 billion trailing-12-month revenue run rate in Q2 2026, with revenue up 71% year-over-year and over 49,000 active patients. The company is expanding its MASH pipeline to 10 assets, primarily for combination with Rezdiffra, targeting weight loss, liver-fat …

Wise Group plc (NASDAQ:WSE) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Nine brokerages have issued a "Moderate Buy" consensus recommendation for Wise Group plc (NASDAQ:WSE), with an average 12-month price target of $16.52. Despite recent legal and regulatory concerns, including investor lawsuits and a Belgian criminal probe, the company reported quarterly earnings of $0.12 per …

Wedge Capital Management L L P NC Buys Shares of 128,845 Theravance Biopharma, Inc. $TBPH

Wedge Capital Management L L P NC recently acquired 128,845 shares of Theravance Biopharma (NASDAQ:TBPH) worth approximately $2.19 million, now owning about 0.25% of the company. Institutional investors hold 99.10% of TBPH, despite the company reporting an adjusted loss and missing revenue expectations in …

Hardy Reed LLC Acquires New Stake in Huntington Bancshares Incorporated $HBAN

Hardy Reed LLC has acquired a new stake in Huntington Bancshares Incorporated (NASDAQ:HBAN), purchasing 536,380 shares valued at approximately $9.51 million, making it their 17th-largest holding. Huntington Bancshares has a "Moderate Buy" consensus rating from Wall Street analysts with an average price target of …

Commerce Bancshares, Inc. $CBSH Shares Sold by Royal Bank of Canada

Santacruz Silver Mining Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026

Cormorant Asset Management (ANL) discloses 3.98M Adlai Nortye ADS position

Cormorant Asset Management, LP and Bihua Chen have reported a beneficial ownership of 3,978,229 American Depositary Shares (ADS) in Adlai Nortye Ltd. (ANL), representing 6.77% of the ADS-equivalent class. This holding is managed through investment funds advised by Cormorant, with Cormorant Global Healthcare Master …

Virginia National Bankshares (NASDAQ:VABK) Raised to "Buy" at Wall Street Zen

Wall Street Zen upgraded Virginia National Bankshares (NASDAQ:VABK) from "Hold" to "Buy," though Weiss Ratings maintained a "Hold (C)" and the overall analyst consensus remains "Hold." The company's stock was trading at $46.79 with a $253.6 million market cap, a P/E ratio of 10.26, …

Milestone’s FDA Win Now Faces A Tougher Test: Sales

Milestone Pharmaceuticals (NASDAQ: MIST) recently gained FDA approval for its lead product, CARDAMYST™ (etripamil) nasal spray, for PSVT. However, the company now faces the challenge of commercializing the product, with early sales and market sentiment being mixed. The success of CARDAMYST depends heavily on …

How Securities Lawsuits Over Trial Disclosures Will Impact Regeneron Pharmaceuticals’ (REGN) Pipeline-Driven Investment Story

Regeneron Pharmaceuticals is facing securities class action lawsuits concerning alleged misleading statements about its Phase III Fianlimab-Libtayo trial. These lawsuits, focusing on disclosure practices regarding trial delays and failure, could influence investor perception of Regeneron's pipeline-driven strategy, especially as the company advances new programs …

Charter Communications (CHTR) Stock Looks Cheap On Earnings But Weak On Debt

Empowered Funds LLC Buys 119,202 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR

Empowered Funds LLC significantly increased its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) by 661.6% in the first quarter, adding 119,202 shares to reach a total of 137,220 shares valued at $8.6 million. This move is part of a broader trend of institutional investment, with …